SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Low isoniazid concentrations in pregnant and postpartum women treated for tuberculosis irrespective of efavirenz-based ART co-treatment - Marije Van Schalkwyk, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Infant exposure to dolutegravir through placental and breastmilk transfer: A population PK analysis of DolPHIN-1 - Laura DickinsonView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Pharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum - Jeremiah MomperView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Infectious disease action plan for the global accelerator for paediatric formulations (GAP-f) - Paul Domanico, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Pharmacological treatment of NASH - Sven Francque, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Population pharmacokinetics of VRC01 in infants and adults - Jerry LiView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Dual Maintenance for HIV: Pro Perspective - José Ramón Arribas, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Dual Maintenance for HIV: Con Perspective - Andrew Hill, MDView Slideset
VAVikram AryaPhD, FCPSlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Drugs abuse and chemsex a new challenge for antiretroviral drug-drug interaction - Tess MartinView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Effect of CYP2b6 metabolizer status on levonorgestrel pharmacokinetics when combined with efavirenz-based antiretroviral therapy - Michelle PhamView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website - Sara GibbonsView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Clinical Case Presentation - Catia Marzolini, PharmD, PhDView Slideset
